LATS1 Polyclonal Antibody, PerCP-Cy5.5 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-2904r-percp-cy55-100uL |
| Product Name | LATS1 Polyclonal Antibody, PerCP-Cy5.5 Conjugated |
| Applications |
WB
IF(IHC-P)
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | PerCP-Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human LATS1 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 9113 |
| Synonyms | Large tumor suppressor homolog 1; Serine threonine protein kinase LATS1; WARTS; WARTS protein kinase; LATS1_HUMAN. |
| Background | The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments. [provided by RefSeq]. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
Frequently asked questions
Which applications is LATS1 Polyclonal Antibody, PerCP-Cy5.5 Conjugated (BS-2904R-PERCP-CY5-5) validated for, and at what dilution?
BS-2904R-PERCP-CY5-5 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does LATS1 Polyclonal Antibody, PerCP-Cy5.5 Conjugated (BS-2904R-PERCP-CY5-5) react with?
Tested reactivity: Human, Mouse, Rat.
How should BS-2904R-PERCP-CY5-5 be stored?
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise LATS1 Polyclonal Antibody, PerCP-Cy5.5 Conjugated (BS-2904R-PERCP-CY5-5)?
KLH conjugated synthetic peptide derived from human LATS1
What are the excitation and emission wavelengths of the PerCP-Cy5.5 conjugate (BS-2904R-PERCP-CY5-5)?
PerCP-Cy5.5 on BS-2904R-PERCP-CY5-5: excitation / emission 482nm/694nm.